Side-by-side · Research reference

PTD-DBMvsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/40 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

PTD-DBM

Wnt Pathway Activator · Fusion Peptide

Topical / SQAdministrationLee 2023 Ryu 2023

Animal-onlyEvidence level

Wnt/β-cateninPrimary pathway

Topical / SQ · Study-dependent

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

PTD-DBM

Vilon

Primary target

CXXC5–Dishevelled protein-protein interaction

Immune cell differentiation pathways, chromatin modification

Pathway

Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibitionLee 2015 Ryu 2023

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Not applicable — pathway derepression rather than receptor agonism

Unknown — no HPA/HPG axis data

Origin

Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

PTD-DBM

Vilon

Wound healing protocol

Hydrogel patch delivery (concentration not disclosed)

Pyrogallol-HA patch, murine model.

—

Hair regeneration protocol

Topical application (exact dose not disclosed)

Wound-induced hair neogenesis model, mice.

—

Evidence basis

Animal models only (mice)

Mouse / in vitro only

Co-administration

Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023

Combined treatment maximized scar reduction.

—

Human translation

No published human studies

—

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Frequency

—

Unknown — literature does not specify chronic administration protocols

Duration

—

Not characterised in humans

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

Half-life

—

Not published — dipeptides typically <10 min plasma t½

04Side Effects & Safety

Parameter

PTD-DBM

Vilon

Reported adverse events

None reported in animal studies

—

Wnt pathway activation risks

Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis

—

Long-term safety

Unknown — no chronic dosing or human data

—

Delivery vehicle effects

HA-PG hydrogel well-tolerated in mice; human translation pending

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

PTD-DBM

·Active malignancy (Wnt pathway involvement in tumorigenesis)
·Pregnancy / lactation (no safety data)

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

PTD-DBM

·History of Wnt-driven tumors
·Skin lesions with uncertain malignant potential

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

PTD-DBM

Vilon

1. Wound Healing Protocol (Animal Model)

Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Hair Regeneration Protocol (Animal Model)

Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. Combination Therapy

PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Storage & Handling

Not disclosed in available literature. Peptide stability and storage conditions not published.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

06Stack Synergy

PTD-DBM

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020